Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

October 1, 2026

Conditions
Multiple SclerosisLong COVIDLong Covid19ObeseObesityObesity, MorbidAcute Leukemia in Remission
Interventions
DRUG

Liraglutide Pen Injector [Saxenda]

A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.

OTHER

Medication Diary

Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.

Trial Locations (1)

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER